Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

fruit

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

Closing the last mile: translating national market access into real-world patient access in the UK

UK market access needs the right conditions nationally, along with subnational investment and delivery locally

- PMLiVE

The Ripple Effect: Why Connection is the Heart of Healthcare Leadership

In the fast-paced environment of clinical medicine, it is easy to focus solely on data and outcomes. However, as Dr. Toyin Nwafor (Gilead Sciences) and Dr. Shirin Mazumder (University of...

Medscape Education

- PMLiVE

Why HCP AI use is now a brand strategy opportunity for pharma

For pharma brands, AI visibility is no longer just a digital question, it is fast becoming a brand strategy imperative

- PMLiVE

The hidden work of turning breakthroughs into outcomes

The “problem” in healthcare comms is rarely what you say, it’s whether people can act on it. This article explains how we design whole-person engagement to turn intent into sustained...

Mednet

- PMLiVE

PMEA welcome Simon Bates as new Chair of the judging panel

Roche and Alnylam share their experiences entering the PMEAs

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Ramping up human-centricity in trial design

Making the experience better for people living with a health condition begins by including them

- PMLiVE

From insight to interaction: how GenAI can strengthen engagement with healthcare professionals

By Phil Wakefield

- PMLiVE

GenAI is a new audience for medcomms: ensure your message is heard

By Rosie Morland and Rayman Vaid

- PMLiVE

Where patient insight meets strategy: measuring what truly matters

By Stephen O’Farrell

- PMLiVE

AstraZeneca’s Baxfendy approved by US FDA for adults with uncontrolled hypertension

Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links